The clinical respiratory journal
-
Randomized Controlled Trial Multicenter Study Comparative Study
Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD.
GSK233705 is a recently developed inhaled anticholinergic being investigated for the potential treatment of chronic obstructive pulmonary disease (COPD). ⋯ All doses of GSK233705 demonstrated bronchodilatory activity and were well tolerated. Although the onset of bronchodilation was rapid, it was not sustained over 24 h making it unsuitable for once-daily dosing.